NCT05308654: Phase 1: A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants with Relapsed or...

NCT05227144: Phase 1: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma Study of ORIC-533 in Relapsed or Refractory Multiple...

NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Modakafusp alfa (Formerly TAK-573)...

NCT05338775: Phase 1: A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor...

GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125 NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in...

NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma FT576 in Subjects With Multiple Myeloma This is a Phase I dose-finding...

NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia NCT05219721:...

NCT05259839: Phase 1: (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for Relapsed/Refractory Multiple Myeloma A Study to...

DREAMM 12 Relapsed & Refractory Myeloma NCT04398745: Phase 1: A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma...

(OriCAR-017) CAR-T Cells Targeting GPRC5D in the Treatment of Relapsed / Refractory Multiple Myeloma (POLARIS) NCT05016778: Phase 1: A...

NCT05020444: Phase 1 - TriPRIL CAR T Cells in Multiple Myeloma This research study involves the study of TriPRIL CAR T Cells for treating...

Talquetamab Phase 1b study NCT05050097: phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple...

NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers The purpose of this study is to find out whether...

NCT04754100: Phase 1 - AGENT-797 in Participants With Relapsed/Refractory Multiple Myeloma This is a Phase 1, open-label study to ...

NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Acute Leukemia, Diffuse Large B-Cell Lymphoma and Multiple Myeloma...

NCT04772989: Phase 1: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies A Study to Evaluate...

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma,...

PERK Inhibitor NCT05027594: Phase 1: Ph I Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Multiple Myeloma Ph I Study of...

NCT05139225: Phase 1: A Study of TTI-621 and TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma A...

NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With...

NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma...

Pavurutamab NCT04998747: Phase 1: A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma...

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma...

NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple...

NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM) NCT04960579: Phase 1:...

NCT04754945: Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis NCT04754945: Phase 1: Isatuximab as...

MAGNETISMM-2 NCT04798586: Phase 1: MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma...

NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma Newly Diagnosed Multiple Myeloma...

Phase 1 Relapsed & Refractory Myeloma A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma The...

NCT04855929: Phase 1: A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer and Multiple Myeloma....

NCT04688853: Phase 1 - A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients This is...

A Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma This is a Phase 1, multicenter, open label, study of...

NCT04570631: Phase 1: Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or...

NCT04354246: Phase 1: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies COM902 (A TIGIT Inhibitor) in Subjects With...

NCT04634435: Phase 1/2: Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma...

MCARH109 CART MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma This study will test the...

UNIVERSAL Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma...

NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma NCT04405167: Phase 1: Tasquinimod for the Treatment...

NCT04613557: Phase 1: Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma...

NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma This is a...

NCT04398680: Phase 1: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function (DREAMM...

NCT04557150: Phase 1: A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of RO7425781 in Participants With Relapsed...

NCT04671251: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma Phase 1b Study of AEVI-007 in Subjects...

NCT04541368: Phase 1: A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy A Study of...

NCT04398485: Phase 1: A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma A Study of ION251 Administered...

Talquetamab and Teclistamab Daratumumab A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or...

CC-98633 CART NCT04394650: Phase 1 - A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With...

NCT04236011: Phase 1: BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma BCMA and CD19 Targeted Fast...